TPG's Strategic Stake in SCHOTT Poonawalla: A New Era for Vaccine Solutions
TPG will acquire a 35% stake in SCHOTT Poonawalla from the Serum Institute of India. This joint venture with SCHOTT Pharma is a global leader in vaccine manufacturing. The collaboration will enhance SCHOTT Poonawalla's market leadership in injectables, with TPG bringing healthcare investment expertise.
- Country:
- India
Global alternative asset management firm TPG is set to acquire a 35 percent stake in the SCHOTT Poonawalla joint venture from the Serum Institute of India (SII), according to a statement released on Tuesday. The financial specifics of the transaction remain undisclosed.
TPG Growth, TPG's middle-market and growth equity platform, will fund the investment, with Novo Holdings acting as a co-investor. Post-transaction, SII will hold a minority stake in SCHOTT Poonawalla, a key player in vaccine manufacturing and a part of the Cyrus Poonawalla Group, noted for its dedication to affordable vaccines.
SCHOTT Pharma CEO Andreas Reisse emphasized India's strategic importance as a manufacturing hub, while SII CEO Adar Poonawalla highlighted TPG's healthcare investment acumen. The transaction, pending customary closing conditions, is anticipated to conclude by the first half of 2025.
(With inputs from agencies.)
- READ MORE ON:
- TPG
- SCHOTT
- Poonawalla
- Serum Institute
- vaccine
- investment
- healthcare
- manufacturing
- India
- innovation
ALSO READ
Redefining Rural Healthcare: Mozambique’s Scalable Model for Global Health Gaps
Litigation, Reformulation, and Investment: A Monday Health News Roundup
Hong Kong's Strategic Investment Shift
Europe's Power Grid Crisis: A Call for Massive Investments
Lama Lobzang: A Guiding Light for Ladakh's Healthcare and Education
Google News